格隆汇9月4日丨红星发展(600367.SH)在投资者互动平台表示，公司充分尊重您对市场的判断，锰元素 在固态电池的研发中扮演着至关重要的角色。公司涉及到锰系产品的产能主要为电解二氧化锰和高纯硫 酸锰，产能均为3万吨/年；同时，公司掌握有四氧化三锰产品生产技术，该产品已经完成中试验证，但 暂无产品产出。 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

证券代码：600367 证券简称：红星发展 公告编号：2025-040 贵州红星发展股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配以方案实施前的公司总股本341,130,902股为基数，每股派发现 金红利0.03元（含税），共计派发现金红利10,233,927.06元。 ? 每股分配比例 A 股每股现金红利0.03元 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/10 | － | 2025/9/11 | 2025/9/11 | | ? 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 贵州红星发展股份有限公司2025 年 5 月 22 日的2024年年度股东会授权董事会 实施公司 2025 年中期利润分配方案，公司 2025 年中期利润分配现金分红金额不 高于 2025 年半年度合并报表归属于上市公司股东的净利润 ...

证券日报网讯 9月2日晚间，红星发展发布公告称，2025年半年度利润分配方案为A股每股现金红利0.03 元（含税），股权登记日为2025年9月10日，除权（息）日及现金红利发放日均为2025年9月11日。 （文章来源：证券日报） ...

证券代码：600367 证券简称：红星发展 公告编号：2025-040 贵州红星发展股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.03元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/10 | － | 2025/9/11 | 2025/9/11 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 贵州红星发展股份有限公司2025 年 5 月 22 日的2024年年度股东会授权董事会 实施公司 2025 年中期利润分配方案，公司 2025 年中期利润分配现金分红金额不 高于 2025 年半年度合并报表归属于上市公司股东的净利润的 30%。本利润分配方 案经公司 2025 年 8 月 21 日召开的第九届董事会第六次会议审议通过。 二、 分配方案 2. 分派对象： 截至股权登记 ...

Core Viewpoint - On August 27, a total of 21 A-share listed companies disclosed their shareholding reduction situations, while Zhonghong Medical announced an increase in shareholding by its general manager [1][2]. Group 1: Shareholding Increase - Zhonghong Medical's general manager, Yang Hao, plans to increase his holdings by no less than 50,000 shares [2]. Group 2: Shareholding Reduction - Keda Intelligent's actual controller, Huang Mingsong, cumulatively reduced his holdings by 4.5 million shares from August 26 to 27 [2]. - Wei Ning Health's directors and senior management, Wang Tao and Wang Li, plan to reduce their shareholdings [2]. - Guoxin Technology's shareholders, including the National Integrated Circuit Industry Investment Fund, plan to collectively reduce their holdings by no more than 5% [2]. - Jingyan Technology's shareholder, Shi Juanhua, intends to reduce his holdings by no more than 0.89% [2]. - Yalian Development's shareholder, Qian Dezhen, plans to reduce his holdings by no more than 2% [2]. - New Network's shareholders, Hongta Innovation and Sun Xiujie, plan to reduce their holdings by no more than 2% [2]. - Hangzhou Garden's shareholders plan to reduce their holdings by no more than 3% [2]. - Dongxin Technology's controlling shareholder and its concerted actors will see their shareholding ratio drop to 37.47% [2]. - Miaokelando's vice chairman and general manager, Chai Zhuo, plans to reduce his holdings by no more than 1.95% [2]. - Fudan Zhangjiang's shareholder, Wang Haibo, plans to reduce his holdings by no more than 0.01% [2]. - Kangchen Pharmaceutical's executive, Niu Zhanqi, plans to reduce his holdings by no more than 87,500 shares [2]. - Fulaite's controlling shareholder and directors intend to collectively reduce their holdings by no more than 2.1333% [2]. - Hehui Optoelectronics' Shanghai Integrated Circuit Industry Investment Fund plans to reduce its holdings by no more than 2% [2]. - Cambridge Technology's controlling shareholder reduced his holdings by 1.8 million shares [2]. - Tuojing Technology's directors and supervisors plan to collectively reduce their holdings by no more than 0.0522% [2]. - Hongxing Development's senior management, Liu Zhengtai, plans to reduce his holdings by no more than 15,300 shares [2]. - Su Bian Electric's executive, Li Daiping, plans to reduce his holdings by no more than 0.03% [2]. - Haohan Depth's Feng Yanjun plans to reduce his holdings by no more than 72,000 shares [2]. - Zhejiang University Network's shareholder, Wangxin Group, plans to reduce its holdings by no more than 0.97% [2]. - Youfa Group's executive, Han Deheng, plans to reduce his holdings by no more than 0.27% [2]. - Hengyin Technology's Wang Shuqin plans to reduce his holdings by no more than 15,615,600 shares [2].

证券代码：600367 证券简称：红星发展 公告编号：2025-039 贵州红星发展股份有限公司 高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 高级管理人员持股的基本情况 截止本公告日，贵州红星发展股份有限公司（下称公司）高级管理人员刘正 涛先生持有公司股份 61,200 股，占公司总股本的 0.0179%，股份来源为限制性 股票激励计划授予取得的股份。 ? 减持计划的主要内容 刘正涛先生因个人资金需求，自本公告披露之日起 15 个交易日后 3 个月内 （窗口期等不减持股份），拟通过集中竞价方式减持其所持有的公司股份合计不 超过 15,300 股，约占公司股份总数的 0.0045%。减持价格根据减持时的市场价 格确定。若减持期间公司有送股、资本公积转增股本等变动事项，应对上述减持 数量做相应调整。 一、减持主体的基本情况 股东名称 刘正涛 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 □是 √否 股东身份 上述减持主体无一致行动人。 二、减持计划 ...

红星发展公告，公司高级管理人员刘正涛持有股份61200股，占0.0179%，因个人资金需求，计划自公 告披露之日起15个交易日后的3个月内，通过集中竞价方式减持不超过15300股，约占公司股份总数 0.0045%，减持期间为2025年9月19日～2025年12月18日，减持价格以减持时市场价格为准。 ...

转自：中国质量报 本报讯 （记者李 嘉）8月22日，贵州省市场监管局公示进入第五届贵州省省长质量奖现场评审环节的12 家企业名单，广泛听取意见，接受社会监督。 据悉，今年3月28日，经贵州省人民政府同意，贵州省市场监管局启动第五届省长质量奖评选表彰工 作，并依据《贵州省省长质量奖管理办法（试行）》和《第五届贵州省省长质量奖评选表彰工作方 案》，明确申报企业或组织应具备的基本条件。7月3日，该局公布60家企业和组织进入第五届贵州省省 长质量奖受理名单。 此次公示进入第五届省长质量奖现场评审环节的12家企业，包括贵阳南明老干妈风味食品有限责任公 司、贵阳中安科技集团有限公司、贵州安吉航空精密铸造有限责任公司、贵州董酒股份有限公司、贵州 航宇科技发展股份有限公司、贵州红星发展股份有限公司、贵州吉利汽车制造有限公司、贵州数据宝网 络科技有限公司、贵州铜仁贵茶茶业股份有限公司、贵州瓮福蓝天氟化工股份有限公司、贵州珍酒酿酒 有限公司、中国航空工业标准件制造有限责任公司（以企业名称拼音顺序排列，排名不分先后）。 ...

Core Viewpoint - Hongxing Development (600367) reported a strong performance in its 2025 mid-year financial results, with significant increases in net profit and profitability metrics compared to the previous year [1]. Financial Performance Summary - Total revenue for the first half of 2025 reached 1.081 billion yuan, a year-on-year increase of 3.68% [1]. - Net profit attributable to shareholders was 78.4425 million yuan, up 233.08% year-on-year [1]. - The gross profit margin improved to 25.84%, reflecting a 48.6% increase compared to the previous year [1]. - The net profit margin rose to 9.27%, marking a substantial increase of 261.84% year-on-year [1]. - Operating cash flow per share increased to 0.48 yuan, a rise of 138.63% compared to the previous year [1]. Key Financial Metrics - The company reported a total of 1.06 billion yuan in combined selling, administrative, and financial expenses, which accounted for 9.82% of revenue, an increase of 10.58% year-on-year [1]. - Earnings per share reached 0.23 yuan, reflecting a significant increase of 228.57% year-on-year [1]. - The company's net assets per share increased to 7.2 yuan, a rise of 5.25% year-on-year [1]. Changes in Financial Items - Accounts receivable decreased by 7.34% to 244 million yuan, attributed to increased sales revenue and credit terms [2]. - Construction in progress saw a significant increase of 89.9%, due to higher expenditures on a project by a subsidiary [2]. - Deferred income increased by 130.78%, linked to government subsidies received during the reporting period [3]. - Research and development expenses rose by 39.98%, indicating increased investment in innovation [4]. Operational Insights - The company experienced a notable increase in cash flow from operating activities, attributed to higher sales revenue [4]. - The return on invested capital (ROIC) for the previous year was reported at 3.4%, indicating a relatively weak capital return [5]. - The company has been under scrutiny regarding its accounts receivable, which reached 274.27% of profit, suggesting potential liquidity concerns [6].